追踪隐球菌性脑膜炎以监测「全员治疗」时代HIV项目成效:博茨瓦纳全国数据分析
该研究利用博茨瓦纳2015至2022年全国脑膜炎监测电子数据,共识别1744例隐球菌性脑膜炎(CM)病例,发病率从2015年的15.0例/10万人年降至2022年的7.4例/10万人年,但2016年推行全员治疗后下降速度放缓。通过隐球菌抗原检测诊断的病例比例从35.5%升至86.3%。
要点
- 博茨瓦纳CM发病率从2015年15.0例/10万人年降至2022年7.4例/10万人年,但2016年全员治疗后下降放缓。
- 男性及40-44岁人群CM发病率最高。
- 通过隐球菌抗原检测诊断的CM比例从35.5%升至86.3%,提示CM可作为项目成效指标。
核心结论
- 博茨瓦纳CM发病率在抗逆转录病毒治疗覆盖扩大后下降,但仍顽固地维持在较高水平;多数病例现通过廉价易用的隐球菌抗原检测诊断,凸显CM可作为「全员治疗」时代项目成功的关键指标。
研究设计与样本
- 研究获取博茨瓦纳2015至2022年全国脑膜炎监测数据,来自政府医疗机构内脑脊液样本的电子实验室记录,并通过与前瞻性队列研究数据集三角互证对缺失数据进行调整;CM病例频率按病例定义枚举,发病率使用全国人口普查数据计算。
主要发现
- 共识别1744例CM病例;发病率从2015年15.0例/10万人年(95%CI 13.4-16.7)降至2022年7.4例/10万人年(95%CI 6.4-8.6)。
- 2016年引入全员治疗后发病率下降速度放缓。
- 男性及40-44岁年龄组发病率最高。
- 通过隐球菌抗原检测诊断的病例比例从35.5%升至86.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cryptococcal meningitis (CM) causes substantial mortality in African countries with a high prevalence of human immunodeficiency virus (HIV), despite advances in disease management and increasing antiretroviral therapy (ART) coverage. Reliable diagnosis of CM is cheap and more accessible than other indicators of advanced HIV disease burden such as CD4 testing or investigation for disseminated tuberculosis; therefore, monitoring CM incidence has the potential to serve as a valuable metric of HIV programmatic success. METHODS: Botswana national meningitis surveillance data from 2015 to 2022 were obtained from electronic health records. All electronic laboratory records from cerebrospinal fluid samples analyzed within government healthcare facilities in Botswana were extracted from a central online repository. Adjustments for missing data were made through triangulation with prospective cohort study datasets. CM case frequency was enumerated using a case definition and incidence calculated using national census data. RESULTS: A total of 1744 episodes of CM were identified; incidence declined from 15.0 (95% confidence interval [CI], 13.4-16.7) cases/100 000 person-years in 2015 to 7.4 (95% CI, 6.4-8.6) cases/100 000 person-years in 2022. However, the rate of decline slowed following the introduction of universal treatment in 2016. The highest incidence was observed in men and individuals aged 40-44 years. The proportion of cases diagnosed through cryptococcal antigen testing increased from 35.5% to 86.3%. CONCLUSIONS: CM incidence has decreased in Botswana following expansion of ART coverage but persists at a stubbornly high incidence. Most cases are now diagnosed through the cheap and easy-to-use cryptococcal antigen test, highlighting the potential of using CM as key metric of program success in the Treat All era.
引用
- Milburn J, Ntwayagae O, Suresh R, et al. Tracking Cryptococcal Meningitis to Monitor HIV Program Success During the Treat All Era: An Analysis of National Data in Botswana. Clin Infect Dis. 2024. PMID: 38330295. doi:10.1093/cid/ciae066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。